Nutriband signs feasibility agreement with Kindeva to develop abuse deterrent fentanyl patch AVERSA

NutriBand Inc.

Agreement combines Nutriband's AVERSA abuse deterrent technology with Kindeva's FDA-approved fentanyl patch.
Partnership focuses on adapting Kindeva's commercial transdermal manufacturing process for AVERSA incorporation.
Kindeva is a CDMO with 50+ years transdermal experience, formerly 3M Drug Delivery Systems.
AVERSA technology covered by patents: US notice of allowance, patents in Europe, Japan, Korea, Russia, Mexico, Australia.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.